ReCode Combines With TranscripTx, Raises $80m For Novel RNA Drugs

 
• By Mandy Jackson

ReCode, whose platform allows for organ-specific delivery of RNA therapies, plans to start clinical trials in 2022 for its two lead programs in primary ciliary dyskinesia and cystic fibrosis.

Molecule of DNA forming inside the test tube equipment.3d rendering,conceptual image.
ReCode's LNP platform can deliver RNA therapeutics and other genetic medicines • Source: Shutterstock

More from Start-Ups & SMEs

More from Business